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Abstract
Background: Enterococci have become major nosocomial pathogens due to their intrinsic and
acquired resistance to a broad spectrum of antibiotics. Their increasing drug resistance prompts us
to search for prominent antigens to develop vaccines against enterococci. Given the success of
polysaccharide-based vaccines against various bacterial pathogens, we isolated and characterized
the immunochemical properties of polysaccharide antigens from five strains of Enterococcus faecalis
and one strain of vancomycin-resistant E. faecium.
Results: We cultured large batches of each strain, isolated sufficient quantities of polysaccharides,
analyzed their chemical structures, and compared their antigenic specificity. Three classes of
polysaccharides were isolated from each strain, including a polyglucan, a teichoic acid, and a
heteroglycan composed of rhamnose, glucose, galactose, mannosamine, and glucosamine. The
polyglucans from all six strains are identical and appear to be dextran. Yields of the teichoic acids
were generally low. The most abundant polysaccharides are the heteroglycans. The six
heteroglycans are structurally different as evidenced by NMR spectroscopy. They also differ in their
antigenic specificities as revealed by competitive ELISA. The heteroglycans are not immunogenic by
themselves but conjugation to protein carriers significantly enhanced their ability to induce
antibodies.
Conclusion: The six clinical strains of enterococci express abundant, strain-specific cell-surface
heteroglycans. These polysaccharides may provide a molecular basis for serological typing of
enterococcal strains and antigens for the development of vaccines against multi-drug resistant
enterococci.
Background
Enterococci are part of the normal flora of the gastrointes-
tinal and genitourinary tracts and colonize the bowels of
more than 90% of healthy humans [1]. Enterococci are
opportunistic pathogens with generally low virulence, but
their intrinsic and increasing acquired resistance to multi-
ple drugs have made them a major cause of nosocomial
infections [2,3]. Enterococci are intrinsically resistant to a
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number of antimicrobial drugs, including cell wall-active
agents, many commercially available aminoglycosides,
and vancomycin – the antibiotic of last resort against
multidrug-resistant bacteria [4-7]. Enterococci can cause
severe invasive infections such as peritonitis, endocarditis,
meningitis, and abscesses in the urinary tract, along surgi-
cal sites, the lung and pleural spaces, facial sinuses, and
peritoneal cavities [8,9]. Because enterococci can spread
rapidly among hospital patients and transfer their antibi-
otic resistance genes widely, even to other bacterial spe-
cies, they may cause epidemics difficult to control and
thus pose a significant threat to public health. The ever-
increasing resistance of enterococci to multiple drugs
prompts us to search for prominent antigens for the devel-
opment of vaccines.
Enterococci are Gram-positive cocci that share morphol-
ogy and Lancefield antigenicity with group D streptococci.
Invasive Gram-positive pathogens, such as Streptococcus
pneumoniae, are often encapsulated with weakly immuno-
genic polysaccharides (PSs). These PSs are major virulence
factors. It has been found that the structural differences
between capsular PSs form the molecular basis of sero-
logic specificity for many species such as S. pneumoniae
[10]. Specific antibodies to S. pneumoniae PSs promote
opsonization and phagocytosis and thereby confer protec-
tion against pneumococcal infection. Many successful
antibacterial vaccines, such as ones against various sero-
types of S. pneumoniae, type b of Haemophilus influenzae,
and group C of Neisseria meningitides, have been devel-
oped based on their capsular PSs; and many other
polysaccharide-based vaccines are under development
[11]. PSs and PS-synthesis genes have been noted to be
widespread among enterococcal strains [12-15]. Entero-
coccal PSs have been demonstrated to play important
roles in enterococcal pathogenesis, such as conferring
resistance to phagocytosis [16]. Furthermore, enterococ-
cal PSs have been proposed as promising vaccine antigens
[17-19].
Among enterococcal species, Enterococcus faecalis and E.
faecium are the two major human pathogens, accounting
for 85–89% and 10–15% of all enterococcal infections,
respectively [8,9]. Previous investigations have revealed
that enterococci express surface PSs analogous to capsules
of other pathogenic bacteria [20-23]. However, only a few
types of enterococcal PSs have been characterized with
respect to their structure and antigenicity, and then only
partially so. It is not known whether strains of enterococci
express different PSs, nor how many types of PSs exist
within the enterococci family. On the hypothesis that cell-
surface PSs of enterococci form an antigenic basis for sero-
typing and are promising vaccine candidates, we investi-
gated and compared the immunochemical properties of
PSs from six clinical strains of enterococci, including five
strains of E. faecalis and one strain of vancomycin-resist-
ant E. faecium.
Results
Three different PSs were isolated from each enterococcal 
strain
To ease the PS isolation and purification, bacteria of each
enterococcal strain were grown in dialyzed Columbia
broth containing only nutrients with size less than 10
kDa, which were removed by dialysis later in the purifica-
tion process. PSs, released by bacterial cells during fer-
mentation, were found negligible when we attempted to
isolate the PSs from the culture medium. Therefore, all PSs
characterized in this study are cell-attached.
Of various enterococcal strains examined in this and our
unpublished studies, three pools of PSs were obtained
from each of the six enterococcal strains, eluting from the
size-exclusion Sephacryl S400 column in the same order
(Fig. 1). The first PS eluted close to the void volume. As
determined by GC-MS analysis of its alditol acetate deriv-
ative (data not shown), this PS consists solely of glucose.
Based on its 1D 1H and 2D 1H-13C HMQC spectra (data
not shown), this PS is a poly-α-D-(1→6)-glucose, i.e., dex-
tran. Dextran was found in all six enterococcal stains in
this study and also in other enterococcal strains (unpub-
lished results). The second PS consisted of disaccharide
repeating units as suggested by NMR analysis. Because of
the low yield of this PS, it was difficult to conduct further
analysis. However, we speculate this PS might be consist-
ent with the previously identified teichoic acid [24]. The
third PS is a complex heteroglycan, as revealed by NMR,
and its structure varies among different strains (see
below). The heteroglycans were the most abundant PSs
isolated from each enterococcal strain. They are relatively
small, with average molecular sizes of ~20 kDa, as com-
pared with the dextran standards.
When blotted with sera raised against whole bacterial
cells, column-eluting fractions corresponding to the dex-
tran-like PS and the teichoic acids were reactive. Because
the dextan-like PS fractions were contaminated with pro-
teins, the immune reactivity is most likely due to the con-
taminants but not the PS. The reactivity of teichoic acids
with immune sera is consistent with previous findings
[23]. The heteroglycans did not react with immune sera
raised against the whole bacterial cells, indicating that
these PSs are not natively immunogenic on the enterococ-
cal cell surface.
Chemical structural analysis of heteroglycans
Monosaccharide composition of the heteroglycans was
identified by GC-MS analysis of their corresponding aldi-
tol acetate derivatives. The analysis revealed that the het-
eroglycans isolated from the six strains of E. faecalis and E.BMC Microbiology 2006, 6:62 http://www.biomedcentral.com/1471-2180/6/62
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faecium  contained the same five monosaccharides,
namely, rhamnose, glucose, galactose, mannosamine,
and glucosamine. Furthermore, the mannosamine and
glucosamine residues were N-acetylated as suggested by
NMR analysis. Although these PSs contain the same com-
ponents, five monosaccharides can form an enormous
number of differently structured PSs by varying their
sequences and linkage sites. Therefore, we relied on NMR
spectroscopy to distinguish these PSs.
The heteroglycans from the six enterococcal strains dis-
play distinct patterns on their 1H-NMR spectra (Fig. 2). In
each spectrum, signals between 5.6 and 4.5 ppm corre-
spond to the anomeric protons of the monosaccharide
components of the PS, and these signals often serve as sig-
natures for differentiating complex carbohydrate struc-
tures. The signals between 4.4 and 3.2 ppm are due to
protons attached to C2-C6 and are poorly resolved due to
the overlapping chemical shifts. The pattern of these sig-
nals, nonetheless, also reveals the similarities and differ-
ences between PSs. The signals at ~2.1 ppm, resulting
from the methyl protons of N-acteyl or O-acetyl groups,
clearly show the different degree of acetylation of each PS.
In addition, the signals at 1.3 ppm that arise from the C-6
methyl protons of rhamnose are indicative of difference
or similarity of the rhamnose component of the PS. Over-
all, the NMR spectral patterns revealed that the PSs from
E. faecium B210860 and E. faecalis strains 324057B, type
II, type V, and R19001 are different. However, the PSs
from E. faecalis strains type V and 68114 have very similar
structure (Fig. 2, bottom two figures). It is possible, in fact,
that these two PSs are identical. The structural elucidation
of these PSs is quite complicated and is part of an ongoing
study.
Immunological characterization of heteroglycans
To verify the antigenic specificity of the six heteroglycans,
we obtained polyclonal antibodies against the heterogly-
can PSs from E. faecium B210860 and E. faecalis type V.
Because these PSs are not immunogenic in its native form,
A typical Sephacryl S400 column elution profile of the three PSs isolated from E. faecium B210860 Figure 1
A typical Sephacryl S400 column elution profile of the three PSs isolated from E. faecium B210860. Elution pro-
files from the five E. faecalis strains are similar. Fractions positive in immunodot blotting with antiserum raised with E. faecium 
B210860 cells are indicated. The dextran fractions are contaminated with proteins as revealed by UV absorbance at 280 nm. 
The heteroglycan fractions are protein-free, positive in carbohydrate assay, and do not react with antisera induced by bacterial 
cells.
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Proton NMR spectra of the heteroglycan PSs from six enterococcal strains Figure 2
Proton NMR spectra of the heteroglycan PSs from six enterococcal strains. The different signal patterns indicate dif-
ferent structures. The PSs from strain V and 68114 have very similar spectra. Note that the signals at ~2.1 ppm are due to N- 
or O-acetyl groups and that the difference in intensity and pattern reveal different acetylation of each PS. Also note that the 
water signal at 4.45 pm has been suppressed in all spectra.
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they were conjugated to tetanus toxoid. Both conjugates
induced high titers of specific antibodies against the PSs.
Therefore, the immunogenicity of these PSs can be signif-
icantly enhanced by conjugation to immunogenic protein
carriers. If their specific antibodies are proven protective
in future investigation, these PSs will become promising
antigen candidates for enterococcal vaccines.
The antisera specific for PSs of E. faecium B210860 or E.
faecalis type V were used to probe the antigenic specificity
of PSs from different enterococcal strains. The ability to
inhibit the binding between these PSs and their specific
antibodies by each of the six PSs was determined by com-
petitive ELISA inhibition. As shown in Figure 3A, the
results of the ELISA study indicate that the PS from the
vancomycin-resistant E. faecium B210860 is significantly
different from E. faecalis PSs. The binding between E. fae-
cium B210860 PS and its antisera was only completely
inhibited by itself. PSs from E. faecalis type II, 68114, and
R19001 did not inhibit this binding even at high PS con-
centrations. Some batches of PSs from E. faecalis 324057B
and type V displayed limited inhibition at high concentra-
tions.
On the other hand, the binding between E. faecalis type V
PS and its specific sera could be inhibited to various per-
centages by the PS from E. faecalis strain 68114, 324057B,
and R19001 (Fig. 3B). E. faecalis type II PS showed mini-
mal cross-reactivity with type V PS, supporting the conten-
tion that these two strains belong to different serotypes.
PS from the vancomycin-resistant E. faecium B210860 did
not show cross-reactivity with the type V PS, which was
confirmed in both inhibition assays (Figs. 3A and 3B). PS
from E. faecalis 68114 is highly cross-reactive with PS type
V (Fig. 3B). Thus, both inhibition experiments and NMR
analysis revealed that PSs from E. faecalis type V and
68114 are highly similar in structure and antigenicity. It is
possible that these two PSs are the same antigen and that
the subtle difference is the result of minor contamination
in these PS preparations.
This study reveals that all six enterococcal strains express
three types of PSs, namely, a large dextran-like polyglu-
can, a medium-sized teichoic acid, and a heteroglycan
with average molecular size of ~20 kDa. This result is in
line with early findings that the PS gene cluster is wide-
spread among E. faecalis strains and that E. faecalis pro-
duces several large and small PSs [13,22]. We are
particularly interested in the heteroglycan PSs, because
they are the most abundant PSs isolated from all six
strains. We also confirmed that the heteroglycans are
located at the cell surface by immunofluoresence spectros-
copy (Fig. 4) although these heteroglycans could be part
of the capsule, cell wall, or both.
Discussion
Various capsular or cell wall enterococcal PSs have been
reported. In 1963, Wicken and Baddiley identified an
intracellular glycerol teichoic acid containing various glu-
cose substituents as the group antigen for group D strep-
tococci, to which enterococci previously belonged [25]. In
1973, Pazur et al. characterized an antigenic PS from E.
faecalis consisting of a main chain of trisaccharide units
Antigenic specificity of enterococcal heteroglycans Figure 3
Antigenic specificity of enterococcal heteroglycans. 
Competitive ELISA inhibition of the binding between E. fae-
cium B210860 PS and its specific antibodies (A) and inhibition 
of the binding between E. faecalis type V PS and its specific 
antibodies (B). Starting dilution of inhibitors were 10 times 
the coating concentrations.
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joined with lactosyl and cellobiosyl side chains [26]. In
1967, Bleiweis et al. reported a type 1 antigen containing
glucose, rhamnose, glucosamine, galactosamine, ribitol,
and phosphorus [27]. In 1999, we characterized a teichoic
acid consisting of glucose, glycerol, and phosphate com-
mon to several enterococcal strains [23,24]. Recently,
Hancock et al. suggested that rhamnopolysaccharides
consisting of rhamnose, glucose, galactose, glucosamine,
and galactosamine are an invariant component of E. faec-
alis cells [22,28]. It is possible that the rhamnopolysaccha-
rides and the heteroglycans in our study belong to the
same category, e.g., they are both expressed at a similar
cell surface location or serve similar functions in entero-
coccal physiology or pathogenesis.
Conclusion
We have isolated and characterized the chemical and
immunological properties of various PSs from six clinical
strains of E. faecium and E. faecalis. Each strain produces
large amounts of a complex heteroglycan consisting of
glucose, galactose, rhamnose, N-acetyl-mannosamine,
and N-acetyl-galactosamine. These PSs are not natively
immunogenic but can be converted to potent immuno-
gens by conjugation to protein carriers. Analysis by NMR
spectroscopy and antigenicity analysis by competitive
ELISA inhibition revealed that heteroglycan PSs from E.
faecium B210860 and E. faecalis types II and V are distinct
antigens. PSs from E. faecalis strains 324057B and R19001
share some epitopes with type V, whereas E. faecalis 68114
PS is highly cross-reactive with type V PS. It is our hope
that the heteroglycans may be used as the molecular basis
for serotyping enterococcal strains and candidate antigens
for the development of vaccines against multi-drug resist-
ant enterococci.
Methods
Strain collection
A total of six clinical enterococcal strains were selected
from a collection of clinical isolates. E. faecalis 68114 and
vancomycin-resistant E. faecium B210860 were isolated
from patients at the Brigham and Women's Hospital in
Boston [23]. E. faecalis 324057B was isolated from a
patient at the Beth Israel Deaconess Medical Center in
Boston [23]. E. faecalis R19001 was an epidemic strain
obtained from Boston Children's Hospital [29]. E. faecalis
type II and type V strains were isolated from patients in
various hospitals in Japan [30]. All isolates were grown in
THB broth and 100-µl aliquots were stored in THB broth
with 10% glycerol at -80°C.
Bacterial culture
To obtain sufficient amounts of PSs for chemical and
immunological analysis, 16-L batch cultures were pre-
pared for each strain in 20-L carboys with Columbia dia-
lysate broth supplemented with 5% glucose and 0.005%
hemin. The dialysate broth was prepared by dialyzing
Columbia broth (Difco Laboratories, Detroit, MI) in
deionized water with a membrane of 10 kDa cut-off to
remove molecules larger than 10 kDa. The pH of the
growth medium were maintained between 7 and 7.2 by
titration with 10 M NaOH through an automatic pH con-
troller (Cole-Parmer Instrument, Vernon Hills, IL), and
the fermentation was terminated when the pH of the
growth medium stabilized without addition of NaOH.
Bacteria were typically grown at 37°C for 16–24 h. Cul-
ture samples were examined for contamination by Gram
staining.
Isolation and purification of PSs
Bacterial cells were harvested by centrifugation at 4°C and
washed in phosphate-buffered saline (PBS, 0.05 M phos-
phate, 0.15 M NaCl, pH 7). PSs were released from cell
pellets by digestion with mutanolysin (50,000 units of
enzyme per 100 g of wet cell) at 37°C for 16 h in 250 ml
of buffer containing 40% sucrose, 30 mM phosphate (pH
7.0), 1 mM MgCl2, and 0.05% NaN3. After centrifugation,
the supernatant was collected, dialyzed extensively against
deionized water at 4°C, and lyophilized. The material was
resuspended in a nuclease buffer (10 mM Tris, 10 mM
CaCl2, and 10 mM MgCl2, pH 7.4) and treated with
RNase A (0.5 mg/ml), DNase (0.1 mg/ml), and RNase T1
(5 µl/ml) at 37°C for 16 h, followed by digestion with
proteinase K (0.1 mg/ml) at 56°C for 16 h. After centrifu-
gation, the supernatant was collected, dialyzed extensively
against deionized water; ethanol was added to a concen-
tration of 30% and the mixture was chilled at 4°C for at
least 6 hours to precipitate contaminating nucleic acids
and proteins. After centrifugation, more ethanol was
added to the supernatant to 80% concentration. PSs were
precipitated at 4°C for 16 h and collected by centrifuga-
Cell surface location of enterococcal heteroglycans Figure 4
Cell surface location of enterococcal heteroglycans. 
Confocal micrograph of E. faecalis type V labeled with rabbit 
antisera specific for type V heteroglycan PS is show as an 
example. Note that these PSs are located at the cell surface.BMC Microbiology 2006, 6:62 http://www.biomedcentral.com/1471-2180/6/62
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tion. Nuclease treatment and 30% ethanol precipitation
were repeated until no significant amounts of proteins or
nucleic acids were detected by UV absorption at 280 nm
for protein contaminants and at 260 nm for nucleic acids
and by ethidium bromide agarose gel for the absence of
DNA.
The crude PS samples were further purified by size-exclu-
sion and ion-exchange chromatography. The PS samples
were first purified on Sephacryl S400 and S200 columns
(Pharmacia Biotech, Piscataway, NJ). Eluted fractions
were monitored by refractive index to detect PS and by UV
absorption at 280 nm to detect protein contaminants. The
carbohydrate content of each fraction was verified by phe-
nol sulfuric acid assay. Fractions were also examined for
immunogenicity by immunoblotting with rabbit antisera
raised against the bacteria. Fractions positive with any of
these four detection methods were pooled, dialyzed
against deionized water, and lyophilized. They were fur-
ther purified on an anion-exchange Q Sepharose column
(Pharmacia Biotech, NJ), eluting with a linear gradient of
NaCl from 0 to 1 M in 50 mM Tris buffer (pH 8.0). Simi-
larly, fractions positive in the phenol-sulfuric acid assay or
immunoblot were pooled, dialyzed, and lyophilized. To
eliminate possible contaminants which may give false
structural information, the heteroglycans were further
purified by Superdex 200 column and analyzed by the
same detection methods above.
Chemical structural analysis of PSs
All PS samples were analyzed by 1H nuclear magnetic res-
onance (NMR) spectroscopy. Sample preparation con-
sisted of 1 mg dissolved in 0.7 ml of D2O. The spectra
were acquired on a Varian Unity 500 spectrometer at
60°C. 1H chemical shifts were referenced to the HDO res-
onance at 4.45 ppm. The water signal was suppressed by
pre-saturation during data acquisition.
Monosaccharide compositions of PSs were determined by
GC-MS analysis of the alditol acetate derivatives as
described [24]. In brief, 0.05 mg of PS sample was com-
pletely hydrolyzed to monosaccharide components with
0.5 ml of 2 M trifluoroacetic acid at 110°C for 2 h, fol-
lowed by reduction to their corresponding alditols with 5
mg of NaBH4 at room temperature for 2 h. Excess NaBH4
was removed by addition of 2 M HCl and drying under a
stream of nitrogen, followed by addition of 0.5 ml of
MeOH and drying under nitrogen. The alditols were con-
verted to peracetates by treatment with 1 ml of 1:1 (vol.)
mixture of acetic anhydride/pyridine at room temperature
for 2 h. The alditol acetate derivatives were subjected to
GC-MS analysis with a DB17 column on a Hewlett-Pack-
ard 6890/5973 GC-MS instrument. The GC run was
started at 180°C, held for 2 min, and increased to 260°C
by 2°C/min, and held at 260°C for 20 min. Standard ald-
itol actetates corresponding to rhamnose, glucose, galac-
tose, mannose, N-acetyl-glucosamine, N-acetyl-
galactosamine, N-acetyl-mannosamine, and other typical
monosaccharides were used for comparison in the GC-MS
analysis.
Preparation of antisera specific for bacterial cells or PSs
Antisera to whole bacterial cells of E. faecalis types II and
V and E. faecium B210860 were prepared. Bacteria were
grown in 500 ml of Todd-Hewitt broth at 37°C until mid-
log phase with OD650 of 0.4–0.5. Bacterial cells were har-
vested by centrifugation, washed with PBS, and fixed with
0.1% formalin at room temperature for 30 min. Three
New Zealand white female rabbits, 1.5 kg, were used for
immunization with the three strains of enterococcal cells.
Rabbits were immunized intravenously with 0.1, 0.3, and
0.5 ml of 7 × 109 cfu/mL bacterial cells on day 1, 3, and 5,
respectively. On the second, fourth, and fifth weeks, the
rabbits was boosted with 0.5 ml of the bacterial cells three
times a week. Immune sera were obtained one week after
the last immunization and used for identification of nat-
urally immunogenic PSs.
Antisera against the PSs from E. faecium B210860 and E.
faecalis  type V were prepared from rabbits immunized
with conjugates of PS to tetanus toxoid. For the conjugate
preparation, 2-mg samples of PSs were oxidized with 0.5
ml of 10 mM NaI4 at room temperature for 90 min, dia-
lyzed, and lyophilized. The oxidized PS was reacted with
2 mg of tetanus toxoid in PBS with the addition of 10 mg
of NaCNBH3. The conjugates were dialyzed and lyophi-
lized. One New Zealand white rabbit, 1.5 kg, was immu-
nized with each of the two conjugates. Rabbits were
immunized three times by subcutaneous injection with
50 µg conjugate on weeks 1, 3, and 6. Complete Freund's
adjuvant was used in the primary injection and incom-
plete Freund's adjuvant was used in the booster injections.
Immune sera were collected one week after the last immu-
nization and used for assessing the antigenic specificity of
PSs.
Fluorescence confocal microscopy
E. faecalis type V and E. faecium B210860 were grown in
glass-bottomed Petri dishes (MatTek, CA) with Todd-
Hewitt broth to mid-log phase as determined by their
growth curves. After being washed with PBS, bacterial cells
were fixed with 1% paraformaldehyde at room tempera-
ture for 30 min. Cells were incubated with diluted (1:250)
specific antisera at 37°C for 90 min, followed by incuba-
tion with Alexa Fluor 488-labeled goat-anti-rabbit IgG
(Molecular Probes, CA) at 37°C for 90 min. Bacterial cells
were washed and viewed by fluorescence confocal micro-
scopy (Bio-Rad 1024MP system, Zeiss axiovert S100 cry-
ton argon laser with 488 filter).BMC Microbiology 2006, 6:62 http://www.biomedcentral.com/1471-2180/6/62
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Competitive ELISA inhibition
Nunc-Immuno microtiter plates were coated with 100 µL
of the selected PS-bovine serum albumin (BSA) conjugate
(1 mg/mL for E. faecalis Type V and 0.25 mg/mL for E. fae-
cium B210860) at 30°C for 4 h. PS-BSA conjugates were
prepared similarly to those of PS-tetanus toxoid as
described above. Plates were then washed with 10 mM
Tris buffer five times. In the meantime, a series of mixing
solutions were prepared on a separate plate by adding
inhibitory PSs in 2-fold serial dilution. The concentrations
of the PS inhibitors started at a concentration of 2.5 mg/
mL (10× coating-antigen) for E. faecium B210860 PS-BSA
coated plates and at 10 mg/mL for E. faecalis Type V PS-
BSA coated plates. The mixing plates were then incubated
at 30°C for 2 h and washed five times, followed by the
addition of 75 µL antisera to each well. For the competi-
tive inhibition, 100-µL solution containing inhibitor and
antisera in the mixing plate was transferred from each well
to the antigen-coated plate. The plate was incubated at
4°C overnight, followed by addition of 100 µL alkaline
phosphatase conjugated goat anti-rabbit IgG to each well.
The plate was incubated at 37°C for 2 h, washed five
times, and 100 µL of substrate solution was added con-
taining 1 mg/mL of p-nitrophenyl-phosphate in bicarbo-
nate buffer (35 mM sodium carbonate, 0.01% w/w
MgCl2, 0.02% w/w sodium azide, pH 10). Absorption at
405 nm was recorded and plotted against molar concen-
trations of the inhibitor. Percentage of inhibition was cal-
culated from the difference with and without inhibitor vs.
control.
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